CARISMA THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.41 USD | +2.92% |
|
-6.62% | -51.88% |
| May. 09 | Carisma Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| May. 02 | Carisma Therapeutics Appoints Dr. Eugene P. Kennedy as Chief Medical Officer | CI |
Valuation
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Capitalization 1 | 118.2 | 56.91 | - | - |
| Enterprise Value (EV) 1 | 118.2 | 56.91 | 56.91 | 56.91 |
| P/E ratio | -1.13 x | -1.09 x | -1.05 x | -1.18 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | 7.93 x | 3.64 x | 4.39 x | 2.51 x |
| EV / Revenue | 7.93 x | 3.64 x | 4.39 x | 2.51 x |
| EV / EBITDA | - | - | - | - |
| EV / FCF | -1.44 x | -1.58 x | -1.12 x | -1.54 x |
| FCF Yield | -69.6% | -63.3% | -89.6% | -65% |
| Price to Book | - | - | - | - |
| Nbr of stocks (in thousands) | 40,357 | 41,543 | - | - |
| Reference price 2 | 2.930 | 1.370 | 1.370 | 1.370 |
| Announcement Date | 4/1/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | 14.92 | 15.62 | 12.96 | 22.67 |
| EBITDA | - | - | - | - | - |
| EBIT 1 | - | -88.73 | -62.24 | -71.89 | -71.54 |
| Operating Margin | - | -594.75% | -398.58% | -554.77% | -315.63% |
| Earnings before Tax (EBT) 1 | - | -86.88 | -57.44 | -68.13 | -66.67 |
| Net income 1 | -61.23 | -86.88 | -57.44 | -68.13 | -66.67 |
| Net margin | - | -582.34% | -367.8% | -525.82% | -294.13% |
| EPS 2 | -54.65 | -2.590 | -1.262 | -1.302 | -1.160 |
| Free Cash Flow 1 | - | -82.31 | -36 | -51 | -37 |
| FCF margin | - | -551.71% | -230.53% | -393.59% | -163.24% |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 4/4/23 | 4/1/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 3.243 | 3.56 | 3.827 | 4.289 | 3.397 | 3.924 | 4.299 | 3.899 | 2.399 | 2.399 |
| EBITDA | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -22.97 | -20.96 | -22.34 | -22.45 | -19.51 | -14.45 | -13.78 | -14.51 | -11.87 | -12.98 |
| Operating Margin | -708.36% | -588.9% | -583.85% | -523.43% | -574.33% | -368.15% | -320.47% | -372.07% | -494.94% | -541% |
| Earnings before Tax (EBT) 1 | -24.53 | -19.79 | -21.4 | -21.16 | -18.98 | -12.99 | -12.35 | -13.12 | -11.33 | -12.51 |
| Net income 1 | -24.64 | -19.88 | -21.4 | -20.96 | -18.98 | -12.99 | -12.35 | -13.12 | -11.33 | -12.51 |
| Net margin | -759.85% | -558.31% | -559.26% | -488.65% | -558.67% | -330.95% | -287.33% | -336.46% | -472.26% | -521.47% |
| EPS 2 | -1.930 | -0.4900 | -0.5300 | -0.4800 | -0.4600 | -0.2975 | -0.2650 | -0.2700 | -0.3133 | -0.3300 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 5/11/23 | 8/10/23 | 11/9/23 | 4/1/24 | 5/9/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - |
| Net Cash position | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow 1 | - | -82.3 | -36 | -51 | -37 |
| ROE (net income / shareholders' equity) | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - |
| Assets 1 | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - |
| Capex 1 | - | - | - | 1 | 2 |
| Capex / Sales | - | - | - | 7.72% | 8.82% |
| Announcement Date | 4/4/23 | 4/1/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
1.41
USD
Average target price
7.5
USD
Spread / Average Target
+431.91%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -51.88% | 56.91M | |
| +9.42% | 114B | |
| +11.84% | 104B | |
| -14.15% | 22.41B | |
| -1.05% | 22.28B | |
| -5.29% | 19.07B | |
| -38.29% | 18B | |
| -4.16% | 17.89B | |
| +7.99% | 14.28B | |
| +36.24% | 12.55B |
- Stock Market
- Equities
- CARM Stock
- Financials Carisma Therapeutics, Inc.
